MindMaze Therapeutics Holding SA (V6M) Stock Price & Analysis
V6M Stock Chart & Stats
- Day’s Range
- EUR 0.17 - EUR 0.17
- 52-Week Range
- EUR 0.14 - EUR 3.40
- Previous Close
- EUR 0.17
- Volume
- 0
- Average Volume (3M)
- 551
- Market Cap
- EUR 28.97M
- Enterprise Value
- EUR 25.46M
- Total Cash (Recent Filing)
- EUR 12.50M
- Total Debt (Recent Filing)
- EUR 1.90M
- Price to Earnings (P/E)
- ―
- Beta
- -19.21
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
High Gross Margin
A gross margin of ~69% provides a durable structural cushion versus peers, implying product or cost advantages on core offerings. Sustained high gross margins give management flexibility to invest in R&D and commercialization while dampening the revenue growth needed to approach operating profitability over time.
Very Low Financial Leverage
Extremely low leverage and a strong equity ratio reduce solvency risk and preserve strategic optionality through clinical cycles. This structural balance-sheet strength supports access to capital, strategic partnerships, and cushioning against development setbacks without urgent refinancing pressure.
Diversified Revenue/funding Model
A business model that includes licensing, milestone payments, royalties, and grants distributes commercial risk and provides non-dilutive funding pathways. Structurally, this reduces dependency on product sales timing and enables capital-efficient advancement of the pipeline through partnerships and staged payments.
Bears Say
Persistent Negative Profitability
Ongoing net losses and negative operating margins indicate the core business is not yet self-sustaining. Over the medium term the company must either achieve sustained positive operating leverage or secure repeated external funding, otherwise cash burn will constrain R&D and commercialization plans.
Negative Free Cash Flow
Negative free cash flow limits the firm's ability to internally fund trials and commercialization costs, forcing reliance on equity or partnership financing. While improvement is positive, durable operational health requires consistent positive FCF to reduce dilution risk and finance long-term growth.
Unprofitable With No Dividend Support
Being unprofitable removes earnings-derived resilience and eliminates dividend income as investor support. Structurally this heightens dependence on capital markets and strategic deals for runway, increasing dilution and execution risk if clinical or commercialization milestones slip.
MindMaze Therapeutics Holding SA News
V6M FAQ
What was MindMaze Therapeutics Holding SA’s price range in the past 12 months?
What is MindMaze Therapeutics Holding SA’s market cap?
When is MindMaze Therapeutics Holding SA’s upcoming earnings report date?
How were MindMaze Therapeutics Holding SA’s earnings last quarter?
Is MindMaze Therapeutics Holding SA overvalued?
Does MindMaze Therapeutics Holding SA pay dividends?
What is MindMaze Therapeutics Holding SA’s EPS estimate?
How many shares outstanding does MindMaze Therapeutics Holding SA have?
What happened to MindMaze Therapeutics Holding SA’s price movement after its last earnings report?
Which hedge fund is a major shareholder of MindMaze Therapeutics Holding SA?
What is the TipRanks Smart Score and how is it calculated?
Company Description
MindMaze Therapeutics Holding SA
MindMaze Therapeutics Holding SA operates as a commercial-stage biopharmaceutical and neurotechnology company in Asia, the United States, Switzerland, rest of Europe, and internationally. The company offers MindPod system, a supervised in-clinic neurorehabilitation system designed to initiate and intensify the recovery journey; MindMotion GO, which extends protocolized neurotherapeutics into outpatient and home settings; MindMotion Companion, an application that manages prescription, monitoring and documentation across MindMaze Therapeutics’ neurotherapeutics ecosystem; and the patient app, a patient-facing mobile application, that supports clinic-to-home continuity by making prescribed therapy easy to follow outside the clinic. It also provides Izar hand therapy device which supports fine motor rehabilitation; Physilog sensor, a wearable inertial sensing device designed to quantify human movement; toaprun, a training for Parkinson’s therapy-reimagined through play. The company was founded in 2012 and is headquartered in Geneva, Switzerland.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Zach W. Henderson
- Employees
- 10
- Website
- mindmazetherapeutics.com
- Address
- Chemin de Roseneck 5, Geneva, GE, 1202, CH
MindMaze Therapeutics Holding SA (V6M) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 9 | 3 | 10 |
| Technical Analysis | 4 | 3 | 3 |
| Moving Averages | 5 | 0 | 7 |